RNA/DNA Polymerase

MB-11362 is a potent, orally active inhibitor of the hepatitis C virus (HCV) NS5B polymerase, functioning as a 4′-azidouridine triphosphate prodrug. Upon oral administration, MB-11362 is converted to its active form, 4′-azidouridine triphosphate, which effectively disrupts viral RNA synthesis. This compound is valuable for research focusing on HCV infection and understanding the mechanisms of antiviral therapies targeting RNA polymerases.

BILB 1941 is a potent nonnucleoside inhibitor targeting the hepatitis C virus (HCV) RNA polymerase. It demonstrates significant antiviral activity in vitro, making it a valuable tool for research applications related to HCV replication and drug development strategies against hepatitis C.

ABT-072 potassium trihydrate is a potent non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, exhibiting EC50 values of 1 nM against HCV genotype 1a and 0.3 nM against genotype 1b. This compound is primarily utilized in research focused on HCV replication and the development of antiviral therapies.

MK3281 is a non-nucleoside inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, with an EC50 of 28 nM for genotype 1a. This compound is utilized in research focused on antiviral drug development and understanding HCV replication mechanisms.

PSI-353661 is a purine nucleotide inhibitor targeting the NS5B polymerase of Hepatitis C Virus (HCV). It demonstrates potent antiviral activity with EC90 values of 8 nM for wild-type HCV and 11 nM for the S282T resistant strain. Additionally, PSI-353661 achieves elevated levels of its active triphosphate form in primary human hepatocytes, making it a valuable tool for studying HCV replication and resistance mechanisms.

HCV NS5B polymerase-IN-3 is a potent inhibitor of the hepatitis C virus (HCV) NS5B polymerase, demonstrating significant antiviral activity. In the Huh7 replicon cell line, it exhibits an EC50 value of 0.23 μM while maintaining a favorable cytotoxicity profile. This compound is relevant for research applications focused on HCV replication and drug development strategies targeting hepatitis C.

VCH-916 free base is a non-nucleoside inhibitor targeting the NS5B polymerase of Hepatitis C virus (HCV). This compound demonstrates potent antiviral activity, making it a valuable tool for research on HCV replication. It is primarily utilized in studies focused on developing effective treatments for Hepatitis C and understanding the viral mechanisms of polymerase function.